Probiotics Clostridium butyricum and Bacillus subtilis ameliorate intestinal tumorigenesis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Wang T, Cai G, Qiu Y et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6(2), 320–329 (2012).•• A good article showed that difference of gut microbiota did exist between colorectal cancer patients and healthy people.
  Medline CASGoogle Scholar
• 2 Zhang L, Cao GT, Zeng XF et al. Effects of clostridium butyricum on growth performance, immune function, and cecal microflora in broiler chickens challenged with Escherichia coli k88. Poultry Sci. 93(1), 46–53 (2014).
  Medline CASGoogle Scholar
• 3 Zhang HQ, Ding TT, Zhao JS et al. Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. World J. Gastroenterol. 15(15), 1821–1828 (2009).
  Medline CASGoogle Scholar
• 4 Kong Q, He GQ, Jia JL, Zhu QL, Ruan H. Oral administration of Clostridium butyricum for modulating gastrointestinal microflora in mice. Curr. Microbiol. 62(2), 512–517 (2011).
  Medline CASGoogle Scholar
• 5 Takahashi M, Taguchi H, Yamaguchi H, Osaki T, Komatsu A, Kamiya S. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli o157: H7 infection in mice. FEMS Immunol. Med. Microbiol. 41(3), 219–226 (2004).
  Medline CASGoogle Scholar
• 6 Chen HM, Yu YN, Wang JL et al. Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma. Am. J. Clin. Nutr. 97(5), 1044–1052 (2013).•• Our previous work suggested that gut microbiota structure was altered in patients with advanced colorectal adenoma.
  Medline CASGoogle Scholar
• 7 Volker U, Hecker M. From genomics via proteomics to cellular physiology of the Gram-positive model organism Bacillus subtilis. Cell. Microbiol. 7(8), 1077–1085 (2005).
  MedlineGoogle Scholar
• 8 Fujiya M, Musch MW, Nakagawa Y et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 1(4), 299–308 (2007).
  Medline CASGoogle Scholar
• 9 Chen S, Fu Y, Liu LL et al. Live combined Bacillus subtilis and Enterococcus faecium ameliorate murine experimental colitis by immunosuppression. Int. J. Inflamm. 2014, 878054 (2014).• This article demonstrated that Bacillus subtilis could ameliorate murine experimental colitis, hinting this probiotics may have a role in colorectal cancer.
  Medline CASGoogle Scholar
• 10 Rescigno M. Intestinal microbiota and its effects on the immune system. Cell. Microbiol. 16(7), 1004–1013 (2014).
  Medline CASGoogle Scholar
• 11 Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8(6), 458–466 (2008).
  Medline CASGoogle Scholar
• 12 Li Y, Deuring J, Peppelenbosch MP, Kuipers EJ, De Haar C, Van Der Woude CJ. IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer. Carcinogenesis 33(10), 1889–1896 (2012).
  Medline CASGoogle Scholar
• 13 Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317(5834), 124–127 (2007).
  Medline CASGoogle Scholar
• 14 Su LK, Kinzler KW, Vogelstein B et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256(5057), 668–670 (1992).
  Medline CASGoogle Scholar
• 15 Kostic AD, Chun E, Robertson L et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14(2), 207–215 (2013).
  Medline CASGoogle Scholar
• 16 Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30(2), 183–196 (2009).
  Medline CASGoogle Scholar
• 17 Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J. Clin. 64(1), 9–29 (2014).
  MedlineGoogle Scholar
• 18 Yam C, Zhao M, Hayashi K et al. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J. Surg. Res. 164(2), 248–255 (2010).
  MedlineGoogle Scholar
• 19 Hiroshima Y, Zhang Y, Murakami T et al. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. Oncotarget 5(23), 12346–12357 (2014).
  MedlineGoogle Scholar
• 20 Hiroshima Y, Zhao M, Maawy A et al. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J. Cell. Biochem. 115(7), 1254–1261 (2014).
  Medline CASGoogle Scholar
• 21 Momiyama M, Zhao M, Kimura H et al. Inhibition and eradication of human glioma with tumor-targeting Salmonella typhimurium in an orthotopic nude-mouse model. Cell Cycle 11(3), 628–632 (2012).
  Medline CASGoogle Scholar
• 22 Kimura H, Zhang L, Zhao M et al. Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif. 43(1), 41–48 (2010).
  Medline CASGoogle Scholar
• 23 Miwa S, Zhang Y, Baek KE et al. Inhibition of spontaneous and experimental lung metastasis of soft-tissue sarcoma by tumor-targeting Salmonella typhimurium A1-R. Oncotarget 5(24), 12849–12861 (2014).
  MedlineGoogle Scholar
• 24 Hayashi K, Zhao M, Yamauchi K et al. Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle 8(6), 870–875 (2009).
  Medline CASGoogle Scholar
• 25 Matsumoto Y, Miwa S, Zhang Y et al. Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J. Cell. Biochemi. 115(11), 1996–2003 (2014).
  Medline CASGoogle Scholar
• 26 Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 361(9356), 512–519 (2003).
  MedlineGoogle Scholar
• 27 Rafter J. The effects of probiotics on colon cancer development. Nutr. Res. Rev. 17(2), 277–284 (2004).
  MedlineGoogle Scholar
• 28 Uccello M, Malaguarnera G, Basile F et al. Potential role of probiotics on colorectal cancer prevention. BMC Surg. 12(Suppl. 1), S35 (2012).•• We can get some basic knowledge in the field we studied.
  MedlineGoogle Scholar
• 29 Mohania D, Kansal VK, Kruzliak P, Kumari A. Probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum modulates the formation of aberrant crypt foci, mucin depleted foci and cell proliferation on 1, 2-dimethylhydrazine induced colorectal carcinogenesis in wistar rats. Rejuv. Res. 325–333 (2014).
  MedlineGoogle Scholar
• 30 Verma A, Shukla G. Probiotics Lactobacillus rhamnosus GG, Lactobacillus acidophilus suppresses DMH-induced procarcinogenic fecal enzymes and preneoplastic aberrant crypt foci in early colon carcinogenesis in Sprague Dawley rats. Nutr. Cancer 65(1), 84–91 (2013).
  MedlineGoogle Scholar
• 31 Arimochi H, Kinouchi T, Kataoka K, Kuwahara T, Ohnishi Y. Effect of intestinal bacteria on formation of azoxymethane-induced aberrant crypt foci in the rat colon. Biochem. Biophys. Res. Commun. 238(3), 753–757 (1997).
  Medline CASGoogle Scholar
• 32 Ohkawara S, Furuya H, Nagashima K, Asanuma N, Hino T. Oral administration of Butyrivibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. J. Nutr. 135(12), 2878–2883 (2005).
  Medline CASGoogle Scholar
• 33 Chen HM, Lin YW, Wang JL, Kong X, Hong J, Fang JY. Identification of potential target genes of butyrate in dimethylhydrazine-induced colorectal cancer in mice. Nutr. Cancer 65(8), 1171–1183 (2013).• Our previous work showed that butyrate could be beneficial in colorectal cancer.
  Medline CASGoogle Scholar
• 34 Isono A, Katsuno T, Sato T et al. Clostridium butyricum TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells. Dig. Dis. Sci. 52(11), 2963–2971 (2007).
  MedlineGoogle Scholar
• 35 Ohnmacht C, Marques R, Presley L, Sawa S, Lochner M, Eberl G. Intestinal microbiota, evolution of the immune system and the bad reputation of pro-inflammatory immunity. Cell. Microbiol. 13(5), 653–659 (2011).
  Medline CASGoogle Scholar
• 36 He D, Li H, Yusuf N et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE 7(2), e32126 (2012).
  Medline CASGoogle Scholar
• 37 Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res. 70(24), 10112–10120 (2010).
  Medline CASGoogle Scholar
• 38 Wu SG, Rhee KJ, Albesiano E et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 15(9), 1016–1022 (2009).
  Medline CASGoogle Scholar
• 39 Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 65(10), 3980–3985 (2005).
  Medline CASGoogle Scholar
• 40 Xiong H, Zhang ZG, Tian XQ et al. Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia 10(3), 287–297 (2008).
  Medline CASGoogle Scholar